Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival

Aza Raza1, Peter Greenberg2, Matthew Olnes3, Lewis R. Silverman4, Francois Wilhelm5

1Columbia University Medical Center, New York, NY, 2Stanford University Cancer Center, Stanford, CA, 3National Heart, Lung and Blood Institute, Bethesda, MD, 4*Mount Sinai Medical Center, New York, NY, 5Onconova Therapeutics Inc, Pennington, NJ

Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome (MDS) – Analysis of Overall Survival (OS) Correlation with Myeloid Blast Response

Abstract

Rigosertib (ON 01910.Na) Hematological Effects in Patients with 50% BM blast decrease from baseline in 33% (13/39) patients

Results

Overall Survival by IPSS Scoring in 51 RAEB-1, -2, -t MDS Patients Treated with Rigosertib

- Overall survival by IPSS scoring in 51 RAEB-1, -2, -t MDS patients treated with Rigosertib.
- Median overall survival was 21 weeks (95% CI: 13-29 weeks) in the High Risk group (IPSS High), 40 weeks (95% CI: 26-54 weeks) in the Int-2 group, and 77 weeks (95% CI: 63-91 weeks) in the Int-1 group. The difference in median overall survival between the High Risk and Int-1 groups was statistically significant (p = 0.0005).

Overall Survival by BM Blast Response in 39 RAEB-1, -2, -t MDS Patients Treated with Rigosertib

- Overall survival by BM blast response in 39 RAEB-1, -2, -t MDS patients treated with Rigosertib.
- Patients with a 50% or greater blast decrease had significantly longer median overall survival (85 weeks) compared to patients without a blast decrease (21 weeks).

Efficacy Conclusions

- Myeloid blast decrease in 30 RAEB-1, -2, -t patients who failed or progressed after receiving hypomethylating agents.
- Best overall response rate in the 39 RAEB-1, -2, -t patients treated with Rigosertib.

Lack of Myelotoxicity

- No change from pre-treatment in BM cellularity over time.

Disclosures: Drs Raza, Greenberg and Silverman received research funding and drug supply from Onconova. Dr Olnes received research funding and drug supply from Onconova. Dr Wilhelm is an Onconova employee.